The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma: two sides of the same coin?

<p>Tissue-resident memory T cells (T<sub>RM</sub> cells) have become an interesting subject of study for antitumor immunity in melanoma and other solid tumors. In the initial phases of antitumor immunity, they maintain an immune equilibrium and protect against challenges with tumor...

Full description

Saved in:
Bibliographic Details
Main Authors: Reschke, Robin Niklas (Author) , Deitert, Benjamin (Author) , Enk, Alexander (Author) , Hassel, Jessica C. (Author)
Format: Article (Journal)
Language:English
Published: 18 March 2024
In: Frontiers in immunology
Year: 2024, Volume: 15, Pages: 1-7
ISSN:1664-3224
DOI:10.3389/fimmu.2024.1385781
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2024.1385781
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1385781/full
Get full text
Author Notes:Robin Reschke, Benjamin Deitert, Alex H. Enk and Jessica C. Hassel
Description
Summary:<p>Tissue-resident memory T cells (T<sub>RM</sub> cells) have become an interesting subject of study for antitumor immunity in melanoma and other solid tumors. In the initial phases of antitumor immunity, they maintain an immune equilibrium and protect against challenges with tumor cells and the formation of primary melanomas. In metastatic settings, they are a prime target cell population for immune checkpoint inhibition (ICI) because they highly express inhibitory checkpoint molecules such as PD-1, CTLA-4, or LAG-3. Once melanoma patients are treated with ICI, T<sub>RM</sub> cells residing in the tumor are reactivated and expand. Tumor killing is achieved by secreting effector molecules such as IFN-γ. However, off-target effects are also observed. Immune-related adverse events, such as those affecting barrier organs like the skin, can be mediated by ICI-induced T<sub>RM</sub> cells. Therefore, a detailed understanding of this memory T-cell type is obligatory to better guide and improve immunotherapy regimens.</p>
Item Description:Gesehen am 28.05.2024
Physical Description:Online Resource
ISSN:1664-3224
DOI:10.3389/fimmu.2024.1385781